ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO735

An Effective Chronic Peritoneal Dialysis Model in Uremic Rats

Session Information

  • Peritoneal Dialysis - II
    November 04, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Dialysis

  • 608 Peritoneal Dialysis


  • Nystrom, Jenny C., University of Gothenburg, Goteborg, Sweden
  • Ebefors, Kerstin, University of Gothenburg, Goteborg, Sweden
  • Haraldsson, Borje, University of Gothenburg, Goteborg, Sweden

Thousands of patients undergo chronic peritoneal dialysis (PD) every day but it has been remarkably difficult to establish experimental models of chronic PD in uremic animals. Such models are needed for tests of new dialysis fluids, new medications and techniques in order to further improve treatment of patients with PD. For that purpose, we have developed a new system for chronic automated PD (APD) in uremic rats.


Rats were made uremic using the nephrotoxin orellanine, a mushroom toxin known to induce uremia through selective destruction of the tubular epithelial cells with no other effects on other organs acutely or chronically, as previously investigated by us both in patients and animal models. The uremic rats and a control group of saline treated rats subsequently underwent APD for three weeks in an automated PD system; one additional set of control rats did not undergo dialysis (n=8 in each group). Each day five exchanges of 15 ml of dialysis fluid (Gambrosol® trio 10) were performed in the APD-system. At the end of the experiment, dialysate, serum and peritoneal tissue were collected for further analysis.


APD worked equally well in both groups of rats. Peritoneal dialysis per se induced elevated expression levels of the growth factors TGF-ß and VEGF in the peritoneal fluid and tissue compared to rats that did not undergo APD. Orellanine treatment did not affect the rats negatively part from the induced uremia. Anuric rats did well on dialysis and continued to grow, albeit at slower pace compared to healthy rats with APD.


This study shows that it is possible to maintain uremic rats for at least three weeks in peritoneal dialysis. The elevated levels of levels of TGF-ß and VEGF in the peritoneal fluid and tissues were found to be due to APD itself, and uremia did not affect these biomarkers significantly. The use of orellanine to induce uremia in rats is an effective option without the side effects commonly seen in surgical models of uremia. We believe that the APD model shown here is a new, effective and reliable model for the testing of new dialysis fluids or new therapeutic targets in uremic animals. We hope this will improve dialysis treatment of patients in the future.


  • Private Foundation Support